Sign up to save your podcasts
Or
Share Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?
In Vivo executive editor Lucie Ellis-Taitt and Infex CEO Peter Jackson explore the current state of antimicrobial resistance in the UK, and worldwide. They discuss the potential of a new “Netflix” style subscription model in the UK for antibiotic reimbursement, as well as future challenges for biotechs in the anti-infectives space.
View all episodes
By Citeline
4.1
2828 ratings
In Vivo executive editor Lucie Ellis-Taitt and Infex CEO Peter Jackson explore the current state of antimicrobial resistance in the UK, and worldwide. They discuss the potential of a new “Netflix” style subscription model in the UK for antibiotic reimbursement, as well as future challenges for biotechs in the anti-infectives space.
More shows like Citeline Podcasts
View all
Marketplace Tech
1,272 Listeners
WSJ Your Money Briefing
1,717 Listeners
WSJ What’s News
4,358 Listeners
Bloomberg Intelligence
409 Listeners
HBR IdeaCast
175 Listeners
How to Be Awesome at Your Job
1,037 Listeners
GZERO World with Ian Bremmer
792 Listeners
The Readout Loud
324 Listeners
Thoughts on the Market
1,302 Listeners
The Journal.
6,086 Listeners
The Next Big Idea
1,284 Listeners
BioCentury This Week
34 Listeners
Coaching Real Leaders
668 Listeners
Biotech Hangout
19 Listeners
HBR On Leadership
161 Listeners